ABSTRACT
Prurigo pigmentosa (PP) is a rare inflammatory dermatosis of unknown cause characterized by a predominantly truncal eruption of pruritic erythematous papules in a reticular pattern, resolving with hyperpigmentation. PP is twice as common in girls and women, and the mean age at onset is 25 years. Diagnosis of PP is challenging and is aided by characteristic histopathologic findings. We report a case of PP in a 17-year-old white boy. The eruption arose during strict adherence to a ketogenic diet.
Subject(s)
Diet, Ketogenic/adverse effects , Doxycycline/therapeutic use , Prurigo/etiology , Adolescent , Biopsy, Needle , Follow-Up Studies , Humans , Immunohistochemistry , Male , Prurigo/drug therapy , Prurigo/pathology , Rare Diseases , Risk Assessment , Severity of Illness Index , Treatment OutcomeSubject(s)
Acrodermatitis/diagnosis , Acrodermatitis/drug therapy , Acrodermatitis/pathology , Adult , Arthralgia/etiology , Female , Humans , Postpartum PeriodSubject(s)
Facial Dermatoses/pathology , Granuloma/pathology , Rosacea/pathology , Sarcoidosis/pathology , Adult , Diagnosis, Differential , Humans , MaleABSTRACT
BACKGROUND: Hyaluronic acid (HA) gels are commonly injected into the skin to lift rhytides and to improve facial appearance. The different processes used in their manufacture and formulation yield products with unique physical characteristics that play an important role in predicting their clinical performance. OBJECTIVE: The following rheologic evaluation was performed to objectively measure the physical characteristics of HA dermal filler products derived from similar bacterial sources and containing the same butanediol diglycidyl ether cross-linker, but formulated using different manufacturing techniques. The objective of this study was to evaluate the physical characteristics of two distinct families of HA products, thereby providing clinicians with a greater understanding of these products' attributes and the ability to optimize their use in the treatment of patients seeking facial rejuvenation. MATERIALS AND METHODS: The physical properties of commercially-available dermal fillers containing HA were evaluated using rheologic testing methods under clinically-relevant conditions. Additionally, light microscopy was used to assess the particulate nature of each product. RESULTS: The gels tested demonstrated a broad range of elasticity, firmness and viscosity. Light microscopy confirmed the particulate nature of each product and revealed HA particles of varying size and distribution. CONCLUSION: This rheologic evaluation demonstrates that differences exist among the HA products tested including gel elasticity, viscosity, and the range and distribution of gel particle sizes. Understanding the distinct physical characteristics of different HA dermal fillers and how these characteristics may predict their clinical behavior can assist clinicians in achieving the desired results in patients seeking facial rejuvenation.
Subject(s)
Butylene Glycols/chemistry , Cosmetic Techniques , Hyaluronic Acid/chemistry , Skin Aging , Cross-Linking Reagents/chemistry , Elasticity , Gels , Humans , Hyaluronic Acid/administration & dosage , Microscopy , Particle Size , Rejuvenation , Rheology , ViscosityABSTRACT
BACKGROUND: Most anticoagulants are not associated with increased risk of severe complications during cutaneous surgery, but no data exist on clopidogrel. OBJECTIVE: We sought to determine frequency and severity of perioperative complications in patients taking clopidogrel-containing anticoagulation. METHODS: This was a retrospective review of medical records of patients undergoing Mohs micrographic surgery at Mayo Clinic, Rochester, MN, while taking clopidogrel-containing anticoagulation between 2004 and 2008, compared with control subjects taking aspirin monotherapy or no anticoagulants. RESULTS: In all, 220 patients taking clopidogrel-containing anticoagulation underwent 363 surgical procedures on 268 occasions. Severe complications occurred in 11 of 363 surgical sites in 10 cases. Clopidogrel-containing anticoagulation was 28 times more likely than no anticoagulation and 6 times more likely than aspirin monotherapy to result in severe complications after Mohs procedures (P < .001 and P = .022, respectively). Severe complications were 8 times more likely after Mohs procedures in patients taking both clopidogrel and aspirin than in control subjects taking aspirin monotherapy (P = .009). No statistically significant difference was found between patients taking clopidogrel monotherapy and control subjects not taking anticoagulants (P = .15). Patients experiencing severe complications were more likely to have larger postoperative surgical sites (P < .001). No thrombotic complications were encountered with discontinuation of clopidogrel-containing anticoagulation; a postoperative thrombotic complication occurred in one patient whose clopidogrel-containing anticoagulation regimen was modified. LIMITATIONS: Retrospective nature of study, possible recall bias as a result of telephone contact, and small number of severe complications were limitations, which reduced study power. CONCLUSION: Cutaneous surgery in patients taking clopidogrel-containing anticoagulation is associated with an increased risk of nonlife-threatening severe complications.
Subject(s)
Anticoagulants/therapeutic use , Dermatologic Surgical Procedures , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Complications/chemically induced , Ticlopidine/analogs & derivatives , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Aspirin/adverse effects , Aspirin/therapeutic use , Clopidogrel , Female , Humans , Male , Middle Aged , Mohs Surgery , Platelet Aggregation Inhibitors/adverse effects , Postoperative Hemorrhage/chemically induced , Ticlopidine/adverse effects , Ticlopidine/therapeutic use , Warfarin/adverse effects , Warfarin/therapeutic useABSTRACT
Erythropoietic protoporphyria is considered a rare disease overall, but in children is the most common form of porphyria, and certainly the most common type of erythropoietic porphyria. Despite this fact, erythropoietic protoporphyria is a disease that has been known to evade or at least delay diagnosis, leading to unnecessary suffering by the patient. Given the distress it may cause a patient and his or her family as well as the potential complications of this disease, the importance of maintaining a heightened awareness when presented with a child complaining of photosensitivity cannot be overstated. This case report will review the important clinical indicators, pathogenesis, histology, diagnosis, management, and treatment of this disease, so that affected children will no longer have to play "hide and seek" when diagnosed with this sun-sensitive disease.
ABSTRACT
Meiotic sex chromosome inactivation (MSCI) during spermatogenesis is characterized by transcriptional silencing of genes on both the X and Y chromosomes in mid-to-late pachytene spermatocytes. MSCI is believed to result from meiotic silencing of unpaired DNA because the X and Y chromosomes remain largely unpaired throughout first meiotic prophase. However, unlike X-chromosome inactivation in female embryonic cells, where 25-30% of X-linked structural genes have been reported to escape inactivation, previous microarray- and RT-PCR-based studies of expression of >364 X-linked mRNA-encoding genes during spermatogenesis have failed to reveal any X-linked gene that escapes the silencing effects of MSCI in primary spermatocytes. Here we show that many X-linked miRNAs are transcribed and processed in pachytene spermatocytes. This unprecedented escape from MSCI by these X-linked miRNAs suggests that they may participate in a critical function at this stage of spermatogenesis, including the possibility that they contribute to the process of MSCI itself, or that they may be essential for post-transcriptional regulation of autosomal mRNAs during the late meiotic and early postmeiotic stages of spermatogenesis.
Subject(s)
Chromosomes, Human, X , MicroRNAs/genetics , X Chromosome Inactivation/genetics , Animals , Chromosomes, Human, Y , Female , Gene Silencing , Humans , Male , Meiosis , Mice , Spermatocytes/physiology , X Chromosome , Y ChromosomeABSTRACT
BACKGROUND: Alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid, capable of binding to all six known retinoid receptors (RAR-alpha, -beta, -gamma, and RXR-alpha, -beta, -gamma). Studies are being carried out to determine how best to utilize this characteristic in treatments for conditions such as chronic hand dermatitis. OBJECTIVE: To review the literature on alitretinoin. METHODS: The scope of the review encompasses ways that alitretinoin is currently and may potentially be utilized. RESULTS/CONCLUSIONS: Orally administered alitretinoin is a safe and effective treatment for chronic hand dermatitis. Topical treatment with alitretinoin can be expanded into other areas such as photoaged skin and cutaneous T-cell lymphoma. Despite these benefits, oral alitretinoin will face a difficult path attaining approval for use in the US.